Hookah, Cigarillos May Be Raising Lung Cancer Rates for Fulton's Black Men
The popularity of hookah lounges, cigar bars, and recreational marijuana may be contributing to higher rates of lung cancer among Black men living in Fulton County, according to recent research outlined by the county's board of health.
Panelists at the Fulton County Board of Health's 'State of Healthcare for African Americans' town hall said on Monday that a higher rate of lung cancer exists among Black men in the region, despite smoking rates often being equal to or lower than that of other racial groups.
'There's something about African Americans that [is] making them more susceptible to the bad effects of tobacco smoke,' Fulton-DeKalb Hospital Authority board trustee Alicia M. Ivey told attendees at the event, which took place at Fulton's South Services Center in College Park.
Dr. Eric L. Flenaugh, a pulmonary medicine expert with Grady Memorial Hospital and the Morehouse School of Medicine, cited research indicating the rate of lung cancer among African American men in Fulton County (74 per 100,000) is about 10 points higher than it is for white men (64 per 100,000), even though both demographics smoke at roughly the same rates (23% versus 25%, respectively).
Flenaugh says Native American men who live in the county smoke at much higher rates (44%) than Black men, but are less likely to get lung cancer.
'It's not just race when we talk about health disparities,' Flenaugh said. 'It's an imbalance between people's health and what they know about their health and what they do with their health and the health care that's available to them or what they seek out.'
The city of Atlanta banned smoking at most public venues in 2020 to help curb growing local respiratory health disparities. But it's allowed in establishments that promote smoking as a form of entertainment, such as hookah lounges and cigar bars, which have become more ubiquitous in Fulton County in recent years.
The Atlanta metro area had the 67th worst level of ozone pollution in the nation last year, according to an American Lung Association report released in April that said Fulton — a majority-Black county — was the worst offender in the region for cancer-causing air particle pollution.
Dr. Lynn Paxton, health director for the Fulton Health District, said the disparities in lung cancer rates among Black Fulton County residents could possibly be attributed to the popularity of products that rival cigarettes in adverse health effects, including hookah, Black and Mild cigarillos, and other cigars.
One Black and Mild has the same nicotine content as about 12.5 cigarettes, according to Flenaugh, who said smoking one full-sized cigar is the same as an entire pack of cigarettes, if not more.
Still, Paxton noted that there's not enough data yet to say conclusively whether hookah use is more likely to cause lung cancer than other tobacco products.
Higher rates of smoking marijuana may also be a problem, according to Flenaugh.
Research shows Black men smoke marijuana at higher rates than other demographic groups. Some Americans believe smoking marijuana is healthier than cigarettes, but Flenaugh noted research showing heavy marijuana users — those who smoke weed 50 times or more throughout their lives — are twice as likely to develop lung cancer.
'I have patients that do that in a week,' Flenaugh said. 'It's starting to become more acceptable. We want to legalize marijuana, but we gotta realize the impact it has, especially for those populations that are more susceptible to the bad effects of smoking.'
Panelists noted that lack of health care access in southern Fulton County, where most Black residents live, may also contribute to higher rates of cancer diagnosis due to lower insurance rates, lack of health care service centers, and overall less cancer screenings in local Black communities.
Quitting smoking, exercising, avoiding venues where secondhand smoke is prevalent, and increasing health care access via full Medicaid expansion were some of the proposed policy solutions.
The post Hookah, Cigarillos May Be Raising Lung Cancer Rates for Fulton's Black Men appeared first on Capital B News - Atlanta.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Alpha Kappa Alpha makes huge global expansion
The post Alpha Kappa Alpha makes huge global expansion appeared first on ClutchPoints. Alpha Kappa Alpha Sorority, Incorporated, chartered a new chapter in London, United Kingdom, broadening its worldwide reach. The sorority established the Alpha Delta Alpha Omega Chapter on May 30. Among the 25 charter members, the women have successful careers in real estate, finance, medicine, business, and other fields. The group's dedication to community involvement has led them to collaborate with over a dozen local groups during the past year. More than 350 Childhood Hunger Power Packs (also known as CHIPP™ weekend meals) have been distributed, more than 200 Blessing Bags have been put together, an eight-week entrepreneurship training program for women has been facilitated, more than 200 volunteer hours have been completed, and more than £3,000 has been invested in Black-owned businesses. With the help of volunteers and visiting sorority members, the chapter will maintain this focus via its first formal service initiatives. Members will plan events like gathering professional clothing for women returning to work and collecting and distributing children's books written by Black writers. 'These women are already making an enormous difference in and around London,' said Carrie J. Clark, International Regional Director for Alpha Kappa Alpha. 'They are an amazing group of servant leaders who I am confident will expand Alpha Kappa Alpha's legacy of service in the Greater London area for years to come.' The sorority has spearheaded several international projects, including building schools in South Africa during apartheid, providing aid to women and children in Liberia, and reducing poverty in sub-Saharan Africa. Additionally, the sorority founded the For Members Only Federal Credit Union, the nation's first Black-owned, female-led, sorority-based digital financial institution. Alpha Kappa Alpha Sorority, Incorporated, is the oldest Greek-letter sorority founded by Black college women. The sorority was founded in 1908 on the Howard University campus in Washington, D.C., by nine collegiate women. With more than 365,000 members, it now has members in over 13 countries and territories, including the United Kingdom.
Yahoo
7 hours ago
- Yahoo
Alphamab Oncology Presented Multiple Clinical Data of Anti-HER2 Biparatopic ADC JSKN003 at the 2025 ASCO Annual Meeting
SUZHOU, China, June 3, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: announced that multiple clinical data updates for anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 were presented as posters at the 2025 Annual Meeting of American Society of Clinical Oncology (2025 ASCO Annual Meeting) from May 30 to June 3, 2025, in Chicago, IL, U.S.. The results covered platinum-resistant ovarian cancer, HER2-positive breast cancer, and HER2-overexpressing gastrointestinal tumors. Title: JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trialsAbstract Number for Publication: 5557Session Type and Title: Poster Session - Gynecologic CancerSession Date and Time: 6/1/2025 9:00 AM-12:00 PM CDTPresenter: Xiaohua Wu, Fudan University Shanghai Cancer Center Methods JSKN003-101 (NCT05494918) is a Phase I study in Australia and JSKN003-102 (NCT05744427) is a Phase I/II study in China. Both trials enrolled patients with advanced solid tumors who were to receive JSKN003 monotherapy at various dose levels. Pooled results have demonstrated that JSKN003 monotherapy has promising efficacy signals in patients with PROC, and the efficacy was observed across patients with (IHC 1+/2+/3+) or without (IHC 0) HER2 expression, with or without prior bevacizumab and prior PARP inhibitor. Preliminary data from the pooled analysis of these two studies were presented at the 2024 European Society for Medical Oncology (ESMO) Congress for the first time. The latest findings for non-primary platinum-refractory PROC patients at a longer follow-up time were reported at this ASCO Annual Meeting. Results As of February 28, 2025, 46 PROC patients were enrolled and received JSKN003 every three weeks across five doses levels, among which 2 patients at the dose of 4.2 mg/kg, 2 patients at the dose of 5.2 mg/kg, 40 patients at the dose of 6.3 mg/kg (RP2D), 1 patient at the dose of 7.3mg/kg, and 1 patient at the dose of 8.4mg/kg. Efficacy: With a median follow-up time of 9.3 months, 46 patients were efficacy evaluable. 42 patients (91.3%) exhibited tumor shrinkage. The objective response rate (ORR) was 63.0%, the median progression-free survival (PFS) was 7.7 months, and the 9-month overall survival (OS) rate was 89.9%. Efficacy was observed across different HER2-expression subgroups. The ORR was 52.4% and the median PFS was 6.6 months in patients with HER2 IHC 0. The ORR reached 72.2% and the median PFS was 9.4 months in patients with HER2 expression (IHC 1+/2+/3+). Safety: Grade 3-4 treatment-related adverse events (TRAEs) occurred in 9 patients (19.6%). Serious TRAEs were reported in 6 patients (13.0%). No TRAEs leading to death. Interstitial lung disease (ILD) was observed in 5 patients (10.9%), all were Grade 1/2. Conclusions With extended follow-up, JSKN003 demonstrated robust PFS improvement in PROC, along with early signals of OS benefit. A confirmatory trial (JSKN003-306, NCT06751485) is currently enrolling all comers regardless of HER2 expression to validate JSKN003 as a treatment option for this patient population. Title: JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studiesAbstract Number for Publication: 1028Session Type and Title: Poster Session - Breast Cancer - MetastaticSession Date and Time: 6/2/2025 9:00 AM-12:00 PM CDTPresenter: Yiqun Du, Fudan University Shanghai Cancer Center Methods The pooled analysis was performed to evaluate the efficacy and safety of JSKN003 in HER2-positive (IHC 3+ or 2+/ISH+) advanced breast cancer from the Phase I clinical trial (JSKN003-101, NCT05494918) in Australia and the Phase I/II clinical trial (JSKN003-102, NCT05744427) in China. Results As of February 28, 2025, the median follow-up duration was 6.1 months. A total of 88 patients with HER2-positive breast cancer were enrolled, with the majority receiving 6.3 mg/kg or 8.4 mg/kg doses. The median age was 55 years (range: 32-79), with 77.3% ECOG PS 1. All patients had stage IV disease, with 76.1% having visceral metastases. All patients had prior anti-HER2 therapy, including 85.2% with prior ADCs or TKIs, and 55.7% having at least three prior lines treatment. Efficacy: A total of 80 T-DXd-naïve patients were enrolled, of whom 75 were evaluable for efficacy. In this population (N=75), JSKN003 demonstrated a confirmed ORR of 54.7% (95% CI: 42.7-66.2). The disease control rate (DCR) and clinical benefit rate (CBR) were 94.7% and 66.7%, respectively. Among 30 patients treated at the RP2D of 6.3 mg/kg, the confirmed ORR was 73.3%, and CBR reached 83.3%. Subgroup analyses by line of therapy showed ORRs of 66.7% in the prior first line group of 15 patients and 63.2% in the prior second line group of 19 patients, respectively. In addition, 8 patients who had previously received T-DXd were enrolled, among whom 7 had evaluable efficacy data. One patient achieved a partial response (PR), four had stable disease (SD), and tumor shrinkage was observed in four patients. These patients were analyzed separately for exploratory purposes. The median duration of response (DoR) in the overall population was 18.4 months (95% CI: 9.9-NE). Median PFS was not mature at the time of data cutoff. The 3-month and 6-month PFS rates were 88.4% (95% CI: 78.8–93.8) and 75.4% (95% CI: 62.3–84.4), respectively. Safety: 15.9% of patients experienced Grade 3 or higher TRAEs. Serious TRAEs were reported in 5.7% of patients. Dose reductions due to TRAEs occurred in 12.5% of patients, and one patient discontinued due to a TRAE. No TRAEs led to death. The most common TRAEs (≥20%) were nausea, increased alanine aminotransferase, decreased white blood cell count, vomiting, anemia, decreased appetite, thrombocytopenia, fatigue, neutropenia, and diarrhea. ILD was reported in 4 patients (4.5%), mostly Grade 1-2; one case was Grade 3. Conclusions JSKN003 demonstrated promising antitumor activity and manageable safety in heavily pretreated HER2-positive breast cancer, including patients previously treated with T-DXd. Its biparatopic HER2 antibody design may enhance target binding and contribute to the observed clinical benefit. A pivotal Phase III trial (JSKN003-301, NCT06846437) is ongoing to compare JSKN003 with T-DM1 in patients with HER2-positive advanced breast cancer who were previously treated with trastuzumab. Title: A pooled analysis of JSKN003, a biparatopic anti-HER2 antibody conjugate (ADC), in patients with advanced HER2-overexpressing (IHC 3+) gastrointestinal tumorsAbstract Number for Publication: 3022Session Type and Title: Poster Session - Developmental Therapeutics - Molecularly Targeted Agents and Tumor BiologySession Date and Time: 6/2/2025 1:30 PM-4:30 PM CDTPresenter: Dan Liu, Beijing Cancer Hospital Methods The pooled analysis was performed to evaluate the efficacy and safety of JSKN003 in HER2-overexpressing (IHC 3+) metastatic gastric cancer or gastroesophageal junction cancer (GC/GEJC) and colorectal cancer (CRC) patients from the Phase I clinical trial (JSKN003-101, NCT05494918) in Australia and the Phase I/II clinical trial (JSKN003-102, NCT05744427) in China. Results As of February 28, 2025, a total of 50 patients with HER2-overexpressing gastrointestinal tumors (27 patients in GC/GEJC and 23 patients in CRC) were enrolled and treated with JSKN003 monotherapy across 7 dose levels: 1 patient at the dose of 2.1 mg/kg, 1 patient at the dose of 4.2 mg/kg, 1 patient at the dose of 5.2 mg/kg, 43 patients at the dose of 6.3 mg/kg, 1 patient at the dose of 7.3 mg/kg, 2 patients at the dose of 8.4 mg/kg and 1 patient at the dose of 10.5 mg/kg. The median age was 60 years (range: 52-66), with 86.0% ECOG PS 1. Most patients were heavily pretreated: 38.0% had at least three lines of prior therapies, 68.0% received anti-HER2 therapy, 48.0% received Irinotecan. Efficacy: Among 48 patients who had at least one tumor assessment after baseline, JSKN003 demonstrated the ORR of 62.5% and the DCR was 93.8%. Among 27 patients with GC/GEJC, the ORR was 63.0% and DCR reached 92.6%. Among 21 patients with CRC, the ORR was 61.9% and DCR reached 95.2%. Among twenty patients with BRAF V600E-wild type, the ORR was 65.0%. Additionally, among 24 patients (4 patients in GC/GEJC and 20 patients in CRC) who were pretreated with irinotecan, the ORR achieved 58.3%. The median DoR in GC/GEJC patients was 9.6 months (95% CI: 3.0-NE), while the median DoR in CRC patients was 12.1 months (95% CI: 5.8-NE). Median PFS was 9.6 months (95%CI: 4.3, 11.6) with 70.4% PFS rate at 6 months in GC/GEJC patients. Median PFS was 13.8 months (95% CI: 6.8, NE) with 88.9% PFS rate at 6 months in CRC patients. Safety: 18.0% of patients experienced Grade 3 or higher TRAEs. Serious TRAEs were reported in 6.0% of patients. Dose reduction due to TRAEs occurred in 20.0% of patients and 16.3% at RP2D. No TEAEs led to discontinuation or death. The most common TRAEs (≥20%) were nausea, diarrhea, decreased appetite, decreased white blood cell count, anemia, fatigue, decreased neutrophil count, decreased platelet count and vomiting. ILD was reported in 3 patients (6.0%), with Grade 1 in 2 patients and Grade 2 in 1 patient. Conclusions JSKN003 demonstrated promising efficacy in heavily pretreated HER2-overexpressing (IHC3+) gastrointestinal tumors including patients previously treated with irinotecan, with a manageable and predictable safety profile. The HER2 biparatopic ADC design may contribute to the observed clinical benefit. About JSKN003 JSKN003 is a bispecific ADC developed based on KN026 using Alphamab's proprietary glycan-specific conjugation platform. JSKN003 can bind HER2 on the surface of tumor cells and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exerting anti-tumor effects. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window. Results of multiple clinical studies at various stages of JSKN003 in China and Australia have demonstrated favorable safety profile, with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors, especially in patients with platinum-resistant ovarian cancer (PROC), HER2-expressing breast cancer (BC), or high HER2-expressing solid tumors. JSKN003 was granted breakthrough therapy designation by CDE. The designation is for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Three Phase III clinical studies of JSKN003 for the treatment of HER2-low expressing BC, PROC, and HER2-positive BC as well as multiple exploratory Phase II clinical studies are currently undergoing smoothly. In September 2024, the Company entered a licensing agreement with JMT-Bio Technology Co., Ltd. ("JMT-Bio"), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: pursuant to which, JMT-Bio was granted the exclusive license and sublicense rights to develop, sell, offer for sale and commercialize JSKN003, for the treatment of tumor-related indications (the "Field") in mainland China (excluding Hong Kong, Macau or Taiwan) (the "Territory") and become the sole marketing authorization holder for JSKN003 for the Field in the Territory. Alphamab retains the sole right to supply JSKN003. About Alphamab Oncology Alphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a product portfolio with differentiated innovation and global competitiveness, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies. The Company has one product approved for marketing (Envafolimab, the world's first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark. Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide. View original content: SOURCE Alphamab Oncology Sign in to access your portfolio
Yahoo
9 hours ago
- Yahoo
Collision near Chick-Fil-A sends one to hospital
SAN ANGELO, Texas (Concho Valley Homepage) — A crash near the Chick-Fil-A on Sherwood sent one person to the hospital. According to the San Angelo Police Department, this collision involved two vehicles near the intersection of Grand Court and FM 2288. A black Toyota RAV4 heading north on FM 2288 when a white Buick Encore was coming out the parking lot by Chick-Fil-A and the driver of the white Buick Encore believed the road was clear when it was not. SADP said the driver of the white Buick Encore failed to yield the right of way to the Black Toyota RAV4. A reporter saw one of the vehicles occupants being lifted off into a stretcher into an ambulance. SAPD confirmed it was the driver of the black Toyota RAV4 for minor injuries. SAPD also said all four occupants of the white Buick Encore didn't have any injuries. SAPD cited the white Buick Encore for failing to yield the right of way. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.